Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 2,406 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dysplasia Mild Clear all
Completed Not applicable Interventional Accepts healthy volunteers

SimpleC Wellness Platform With Social Robot Interaction (Long-term)

NCT05599503
View directory record Official record
Conditions
Engagement, Patient, Quality of Life, Mood, Aging Well, Cognitive Change, Mild Cognitive Impairment, Cognitive Impairment, Dementia
Interventions
Behavioral Interventions, Robot Interventions
Behavioral
Lead sponsor
SimpleC, LLC
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Athens, Georgia • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 31, 2026, 1:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Testing mTBI in Athletes

NCT02486003
View directory record Official record
Conditions
Mild Traumatic Brain Injury, Brain Concussion
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 40 Years
Enrollment
329 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 31, 2026, 1:21 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients

NCT03571620
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Q301 Cream, Vehicle
Drug
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
12 Years to 70 Years
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Oct 31, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease

NCT00930059
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
PF-04447943, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years to 85 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
22
States / cities
Northport, Alabama • Costa Mesa, California • Glendale, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 31, 2026, 1:21 AM EDT
Completed Phase 2 Interventional Results available

Treatment With Omalizumab to Improve the Asthmatic Response to Rhinovirus Experimental Infection With Rhinovirus

NCT02388997
View directory record Official record
Conditions
Asthma
Interventions
omalizumab, Rhinovirus (strain 16)
Drug · Biological
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 40 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Oct 31, 2026, 1:21 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

NCT05399888
View directory record Official record
Conditions
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
Interventions
Diranersen, Diranersen-matching placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 80 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sun City, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 31, 2026, 1:21 AM EDT
Terminated Phase 3 Interventional Results available

Long-Term Study of IGIV, 10% in Alzheimer´s Disease

NCT01736579
View directory record Official record
Conditions
Alzheimer´s Disease
Interventions
Immune Globulin Intravenous (Human), 10% (IGIV, 10%)
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
51 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 31, 2026, 1:21 AM EDT
Terminated Not applicable Interventional

Memory Training and Neural Plasticity

NCT05380739
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Working Memory Training
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
60 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 31, 2026, 1:21 AM EDT
Recruiting Phase 2 Interventional

A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis

NCT07013201
View directory record Official record
Conditions
Palmoplantar Pustulosis
Interventions
Delgocitinib cream, Vehicle cream
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Fountain Valley, California • Douglasville, Georgia • West Bloomfield, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 31, 2026, 1:21 AM EDT
Recruiting Phase 4 Interventional

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

NCT04314375
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Low Dose Budesonide, High Dose Budesonide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Garden Grove, California • Indianapolis, Indiana • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 31, 2026, 1:21 AM EDT
Completed Phase 1 Interventional

A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies

NCT00343798
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Previously Treated Myelodysplastic Syndromes, Prolymphocytic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Childhood Lymphoblastic Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage II Childhood Lymphoblastic Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Childhood Lymphoblastic Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Childhood Lymphoblastic Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma
Interventions
cyclophosphamide, fludarabine phosphate, cyclosporine, mycophenolate mofetil, ex-vivo umbilical cord blood expansion, double-unit umbilical cord blood transplantation, biopsy, immunologic technique, diagnostic laboratory biomarker analysis
Drug · Other · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months to 45 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
4
States / cities
Duarte, California • Aurora, Colorado • Denver, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Oct 31, 2026, 1:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Designing a Spatial Navigation Intervention Protocol Informed by Region-specific Brain Activation for Mild Cognitive Impairment

NCT07225400
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI)
Interventions
Spatial Navigation training
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Manhattan, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 31, 2026, 1:21 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma

NCT00667992
View directory record Official record
Conditions
Asthma
Interventions
Budesonide HFA, Budesonide CFC
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 31, 2026, 1:21 AM EDT
Completed Not applicable Interventional

Walking on Cognitive Function in Individuals With Mild Cognitive Impairment: A Pilot Project

NCT04498195
View directory record Official record
Conditions
Cognitive Impairment, Mild
Interventions
increased exercise and physical activity
Behavioral
Lead sponsor
Samuel Merritt University
Other
Eligibility
60 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Oct 31, 2026, 1:21 AM EDT
Completed Phase 1 Interventional Results available

Mild, Moderate and Severe Renal Impairment Study

NCT02219516
View directory record Official record
Conditions
Gout
Interventions
RDEA3170
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 85 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 31, 2026, 1:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurotrack Test Validation Protocol

NCT02608021
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
60 Years to 85 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 31, 2026, 1:21 AM EDT
Not listed Phase 2 Interventional

Allogeneic Human Mesenchymal Stem Cells for Alzheimer's Disease

NCT02833792
View directory record Official record
Conditions
Alzheimer Dementia
Interventions
Human Mesenchymal Stem Cells and Lactated Riunger's Solution, Placebo
Drug · Other
Lead sponsor
Stemedica Cell Technologies, Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 31, 2026, 1:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of SB-497115 in Healthy Subjects and Subjects With Mild, Moderate or Severe Renal Impairment

NCT00442871
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
2
States / cities
Gainesville, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 31, 2026, 1:21 AM EDT
Recruiting Not applicable Interventional

Effect of Electro-Acupuncture on Blood Pressure

NCT00932139
View directory record Official record
Conditions
Hypertension
Interventions
Electro-acupuncture control, Electro-acupuncture test
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2027
U.S. locations
2
States / cities
Irvine, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 31, 2026, 1:21 AM EDT
Completed Phase 2 Interventional

Phase 2A Study of GM 608 in Mild to Moderate Parkinson Disease

NCT01850381
View directory record Official record
Conditions
Parkinson's Disease
Interventions
GM608, Placebo Comparator
Drug
Lead sponsor
Genervon Biopharmaceuticals, LLC
Industry
Eligibility
30 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2019 · Synced Oct 31, 2026, 1:21 AM EDT
Completed Not applicable Interventional

Cognitive and Aerobic Resilience for the Brain

NCT02390453
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Combined Cognitive and Physical, Cognitive, Physical, Active Control
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 31, 2026, 1:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination Tablet

NCT02108639
View directory record Official record
Conditions
Hepatitis C
Interventions
DCV 3DAA FDC, BMS-791325
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Oct 31, 2026, 1:21 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate Albumin and Immunoglobulin in Alzheimer's Disease

NCT01561053
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Albumin 5%, Albumin 20%, Immunoglobulin
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
55 Years to 85 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
22
States / cities
Sacramento, California • Denver, Colorado • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Oct 31, 2026, 1:21 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Does Computerized Cognitive Training Improve Executive Functioning in the Older Adult?

NCT03170492
View directory record Official record
Conditions
Cognitive Impairment, Mild, Executive Dysfunction
Interventions
RehaCom Computerized Cognitive Training for 480 minutes, Pencil-and-Paper Cognitive Training for 480 minutes
Other
Lead sponsor
University of the Sciences in Philadelphia
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 31, 2026, 1:21 AM EDT